SNAP-GWAS: An integrated precision medicine platform to predict antibiotic treatment outcomes in SNAP
- A large amount of variation exists within the genome of pathogenic Staphylococcus aureus that can be observed between regions or even individuals. These genetic differences can affect how the pathogen interacts with the host and administered treatments.
- These genetic differences could affect the optimal treatment regimen for any one individual with a Staphylococcus aureus bloodstream infection.
- This study aims to use a computational approach to compare the genomes of different strains of S. aureus pathogens to identify markers that can be used to steer clinicians' decisions to the best possible treatment option at a targeted, individual level.
- Phase 1: proof-of-concept study including 200 Australian methicillin-susceptible S. aureus (MSSA) isolates. Preliminary data from this study will be leveraged towards a larger grant (Complete).
- Phase 2: extension of the study to the entire collection including baseline SNAP isolates and isolates from persistent (> 5 days) or recurrent infections (Abandoned/On Hold due to funding limitations).
Lead Investigator: Dr. Stefano Giulieri - University of Melbourne, The Peter Doherty Institute for Infection and Immunity.
Email: stefano.giulieri@unimelb.edu.au
